FTO and acute myeloid leukemia: The Saikosaponin D inhibitor targeting FTO has been indicated to decrease AML cell proliferation and tumor outgrowth, as well as resistance to tyrosine kinase inhibitors in vitro and in vivo by enhancing the overall m6A level of the downstream target genes 219.